G1SK34:BVMF
Gsk Plc Bdr
R$50.20
arrow_downward
-0.59%(-0.30) 1D
Oct 19, 12:15:39 PM GMT-3 · BRL
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for G1SK34...
Open
R$50.35
High
R$50.35
Low
R$50.20
Mkt. cap
100.17B
Avg. vol.
218.00
Volume
28.00
52-wk high
R$63.24
52-wk low
R$46.15
Shares outstanding
4.32B
No. of employees
67K
Open
R$50.35
High
R$50.35
Low
R$50.20
Mkt. cap
100.17B
Avg. vol.
218.00
Volume
28.00
52-wk high
R$63.24
52-wk low
R$46.15
Shares outstanding
4.32B
No. of employees
67K
News stories
From web sources and news partners
GuruFocus
·
22 minutes ago
AnaptysBio (ANAB) Shares Rise After GSK's FDA Label Expansion fo
Investing.com Canada
·
2 hours ago
GSK’s Jemperli wins FDA approval for rectal cancer treatment By Investing.com
REBusinessOnline
·
6 hours ago
GSK to Invest $800M in Metro Philadelphia Life Sciences, Manufacturing Facilities, Create 300 New Jobs
Investing.com
·
12 hours ago
GSK’s Ris-Rez shows 61% response rate in small cell lung cancer trial
Profile
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
About Gsk Plc Bdr
CEOEmma Walmsley | Emma Walmsley
Employees66.8K
FoundedDec 27, 2000
Headquarters-
SectorPharmaceutical industry
Websitegsk.com